Document Detail

Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation.
MedLine Citation:
PMID:  15359268     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the clinical and visual outcome of an intravitreal injection of triamcinolone in patients with diabetic macular oedema refractory to laser treatment. MATERIAL AND METHODS: Prospective, interventional nonrandomised case series of 24 eyes of 24 patients that underwent intravitreal injection of 4 mg triamcinolone for chronic diabetic macular oedema refractory to previous laser treatment. All patients had best corrected visual acuity (bcva) on the LogMAR scale, near vision, slit-lamp biomicroscopy for the presence of clinically significant macular oedema, and intraocular pressure check at 1, 3, and 6 months. RESULTS: The average duration of macular oedema before the injection was 38.2 months (range=6-120 months) with the mean number of laser treatments before the injection being 2.2 (range=1-5). The visual acuity improved in 19 of the 23 (83%) eyes at 1 month, 16 of the 21 eyes (76%) at 3 months and six of 11 eyes (55%) at 6 months follow-up. The mean bcva improved by an average of 10, nine, and six letters, respectively, compared to the baseline at 1, 3, and 6 months (P=0.0002 at 1 month and 0.001 at 3 months with the Wilcoxon signed-ranked test). The intraocular pressure rose by an average of 2.4, 2.8, and 2.7 mmHg at the same follow-up visits. CONCLUSION: Intravitreal triamcinolone appears to be promising in the short term, for improving the vision in eyes with chronic diabetic macular oedema unresponsive to conventional laser treatment. Randomised controlled trials utilising varying doses of steroid are now required to define optimum treatment regimens.
A K Negi; S A Vernon; C S Lim; K Owen-Armstrong
Related Documents :
18708258 - Ranibizumab for the treatment of macular edema associated with perfused central retinal...
24737258 - Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe s...
17021318 - Ranibizumab for neovascular age-related macular degeneration.
11986098 - Intravitreal triamcinolone for refractory diabetic macular edema.
23011528 - Mortality and long-term functional outcome associated with intracranial pressure after ...
21952068 - A study on sexual function of men with anterior urethral stricture before and after tre...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Eye (London, England)     Volume:  19     ISSN:  0950-222X     ISO Abbreviation:  Eye (Lond)     Publication Date:  2005 Jul 
Date Detail:
Created Date:  2005-07-06     Completed Date:  2005-10-25     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  8703986     Medline TA:  Eye (Lond)     Country:  England    
Other Details:
Languages:  eng     Pagination:  747-51     Citation Subset:  IM    
Department of Ophthalmology, Eye and ENT Centre, University Hospital, Nottingham, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / therapeutic use
Diabetic Retinopathy / drug therapy*,  physiopathology
Follow-Up Studies
Glucocorticoids / therapeutic use*
Laser Coagulation
Macular Edema / drug therapy*,  physiopathology
Middle Aged
Prospective Studies
Treatment Failure
Treatment Outcome
Triamcinolone Acetonide / therapeutic use*
Visual Acuity / drug effects*
Vitreous Body
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Glucocorticoids; 76-25-5/Triamcinolone Acetonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of disposable prism tonometry in routine clinical practice.
Next Document:  Photodynamic therapy for maculopathy due to radiation retinopathy.